GI Malignancies Debate 2023 - Chicago | Alliance trials: Combination of modified FOLFIRINOX and radiotherapy for pancreatic cancer

Joseph Herman, MD, MSc, MHCM, Northwell Health Cancer Institute, New Hyde Park, NY, discusses the impact that two Alliance trials, investigating radiotherapy and modified FOLFIRINOX, had on patients with pancreatic cancer. Modified FOLFIRINOX is a combination of four chemotherapy drugs. Results from trial A021101, which investigated the safety of administering modified FOLFIRINOX followed by chemoradiotherapy, revealed that this could be a feasible treatment in patients with pancreatic cancer. In the A021501 randomized trial, patients treated with modified FOLFIRINOX in followed by hypofractionated radiotherapy had lower survival rates compared to treatment with modified FOLFIRINOX alone. It is important to note that this was a small study and patients were randomized upon diagnosis. An additional finding was that the rate at which blood vessels were able to reconstruct in the A021101 trial was higher than in trial A021501. This interview took place at the Great Debates and Updates GI Malignancies Debate in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.